GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs [Yahoo! Finance]
GeoVax Labs, Inc. (GOVX)
NASDAQ:AMEX Investor Relations:
geovax.com/contact-geovax.html
Company Research
Source: Yahoo! Finance
7 min read In This Article GOVX GOVXW Strategic Progress Across COVID-19, Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum ATLANTA, GA - February 5, 2025 ( NEWMEDIAWIRE GeoVax Labs, Inc. (Nasdaq: GOVX) a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today outlined its 2025 strategic milestones and business outlook. Building on a history of delivering on key commitments, GeoVax enters 2025 with a robust pipeline, a catalyst-rich milestone schedule, and an unwavering commitment to addressing unmet medical needs on a global scale. An Important Year Ahead for GEO-CM04S1, a Next-Generation COVID-19 Vaccine GEO-CM04S1 continues to demonstrate potential for both immunocompromised patients and as a booster vaccine for those previously inoculated with mRNA vaccines. In 2025, the Company anticipates completion of the evaluation trial among Chronic Lymphocytic Leukemia (CLL) pat
Show less
Read more
Impact Snapshot
Event Time:
GOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOVX alerts
High impacting GeoVax Labs, Inc. news events
Weekly update
A roundup of the hottest topics
GOVX
News
- GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine [Yahoo! Finance]Yahoo! Finance
- GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026 [Yahoo! Finance]Yahoo! Finance
- GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design [Yahoo! Finance]Yahoo! Finance
- GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients [Yahoo! Finance]Yahoo! Finance
- GeoVax Addresses Identification of New Mpox Variant [Yahoo! Finance]Yahoo! Finance
GOVX
Earnings
- 11/13/25 - Miss
GOVX
Sec Filings
- 12/12/25 - Form S-1
- 11/26/25 - Form 8-K
- 11/7/25 - Form SCHEDULE
- GOVX's page on the SEC website